stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Net income
BridgeBio Pharma, Inc.'s net income for fiscal 2025 was −$732.9M, compared with −$543.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$577.6M. Over the past ten years it has ranged from −$732.9M (fiscal 2025) to −$43.8M (fiscal 2017) — the current reading is the lowest in ten years. BridgeBio Pharma, Inc. ranks 591st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$732.9M | — |
| FY2024 | −$543.3M | — |
| FY2023 | −$653.3M | — |
| FY2022 | −$484.7M | — |
| FY2021 | −$586.5M | — |
| FY2020 | −$505.5M | — |
| FY2019 | −$288.6M | — |
| FY2018 | −$169.5M | — |
| FY2017 | −$43.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$60.5M | — |
| Jun 2026 | −$155.9M | — |
| Mar 2026 | −$166.6M | — |
| Dec 2025 | −$194.6M | — |
| 30 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| HALO Halozyme Therapeutics, Inc. compare | $485.4M |
| JAZZ Jazz Pharmaceuticals PLC compare | $206.0M |
| TECH Bio-Techne Corp compare | $181.9M |
| BMRN BioMarin Pharmaceutical Inc. compare | −$19.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$349.4M |
| BBIO BridgeBio Pharma, Inc. | −$577.6M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BBIO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement